59P - Platelet-derived growth factor (PDGF)-CC serum as clinical outcome predictor after six cycles of chemotherapy in colorectal cancer at RSMH Palembang

Background

Cancer is one of the main problems in the world due to a significant increase in incidences and mortality. Data from the Global Burden of Cancer (Globocan) in 2020, shows colorectal cancer as the third most common cancer and accounts for the third-highest mortality rate. In the Asian region; Indonesia is one of the countries reported to have the lowest incidence and mortality rates compared to other countries due to limited screening and diagnostic. The course of colorectal cancer, from tumorigenesis to metastasis, is a multifactorial process, ranging from cancer stem cells, genetic mutations, and microtumor environment, to various hematological cells. In particular, platelets play a role through the release of growth factors and proinflammatory cytokines from the breakdown of granules stored in the cytoplasm of activated platelets due to cancer. The specific growth factor released by platelets is Platelet-Derived Growth Factor (PDGF), which can be PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD ligands. Of these various classes of PDGF, PDGF-CC has the best ability to predict the progression of colorectal cancer, because it increases during invasion and metastasis. The role of PDGF-CC in various cases of solid and blood cancer showed a strong relationship between the high expression of PDGF-CC with cancer cell aggressiveness and treatment resistance.

Methods

This study is a prognostic test with a prospective cohort design. The study population was colorectal cancer patients who planned adjuvant chemotherapy, from August 2020 to March 2021. The data was processed using SPSS version 26.0.

Results

After assessing the clinical outcome in the form of response to chemotherapy treatment, the subjects were divided into a non-responder group of 52 people (74.3%) and a group of 18 respondents (25.7%). The cut-off point for serum PDGF-CC that can be used to predict this clinical outcome is 365 pg/mL, with a p-value 0.005 (multivariate analysis), OR 4.1 (95% CI 1.32 – 12.86). Table: 59P

Conclusions

Serum PDGF-CC can be used as a good prognostic marker in colorectal cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.